Company launches generic version of alpha-blocker for BPH

Mylan Inc. recently announced that its subsidiary, Mylan Pharmaceuticals Inc., has launched alfuzosin hydrochloride extended-release tablets, 10 mg, for signs and symptoms of BPH.

The tablets are the generic version of Uroxatral, which had U.S. sales of approximately $241 million for the 12 months ending June 30, 2011, according to IMS Health.